Detection of clinically relevant genetic and transcriptomic landscape in DLBCL uniformly treated by R-CHOP

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001003783	Recent studies using next-generation sequencing strategies have described the landscape of genetic alterations in diffuse large B-cell lymphoma (DLBCL). However, little is known about the clinical relevance of recurrent mutations and copy number alterations and their transcriptional footprints. This study examines the frequency, interaction and clinical impact of recurrent genetic aberrations in DLBCL using high-resolution technologies in a large population-based cohort.	Illumina HiSeq 2000 Illumina HiSeq 2500	376
EGAD00010001980	Affymetrix SNP6.0 data for 341 DLBCL patients	Affymetrix SNP6.0	341

Publications	Citations
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Ennishi D, Healy S, Bashashati A, Saberi S, Hother C, Mottok A, Chan FC, Chong L, Abraham L, Kridel R, Boyle M, Meissner B, Aoki T, Takata K, Woolcock BW, Viganò E, Gold M, Molday LL, Molday RS, Telenius A, Li MY, Wretham N, Dos Santos N, Wong M, Viller NN, Uger RA, Duns G, Baticados A, Madero A, Bristow BN, Farinha P, Slack GW, Ben-Neriah S, Lai D, Zhang AW, Salehi S, Shulha HP, Chiu DS, Mostafavi S, Gerrie AS, Huang DW, Rushton C, Villa D, Sehn LH, Savage KJ, Mungall AJ, Weng AP, Bally MB, Morin RD, Cohen Freue GV, Staudt LM, Connors JM, Marra MA, Shah SP, Gascoyne RD, Scott DW, Steidl C. Nat Med 26: 2020 577-588	29
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, Jiang A, Bagaev A, Plotnikova O, Kotlov N, Johnson CA, Wilson WH, Scott DW, Staudt LM. Cancer Cell 37: 2020 551-568.e14	272
Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. Holmes AB, Corinaldesi C, Shen Q, Kumar R, Compagno N, Wang Z, Nitzan M, Grunstein E, Pasqualucci L, Dalla-Favera R, Basso K. J Exp Med 217: 2020 e20200483	59
PRPS-ST: A protocol-agnostic self-training method for gene expression-based classification of blood cancers. Jiang A, Hilton LK, Tang J, Rushton CK, Grande BM, Scott DW, Morin RD. Blood Cancer Discov 1: 2020 244-257	1
Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors. Shanmugam V, Craig JW, Hilton LK, Nguyen MH, Rushton CK, Fahimdanesh K, Lovitch S, Ferland B, Scott DW, Aster JC. Blood Adv 5: 2021 71-83	7
Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. Roberto MP, Varano G, Vinas-Castells R, Holmes AB, Kumar R, Pasqualucci L, Farinha P, Scott DW, Dominguez-Sola D. Immunity 54: 2021 1807-1824.e14	9
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, Kurtz DM, Liu CL, Khameneh F, Advani RH, Natkunam Y, Myklebust JH, Diehn M, Gentles AJ, Newman AM, Alizadeh AA. Cancer Cell 39: 2021 1422-1437.e10	43
Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. Donati G, Ravà M, Filipuzzi M, Nicoli P, Cassina L, Verrecchia A, Doni M, Rodighiero S, Parodi F, Boletta A, Vellano CP, Marszalek JR, Draetta GF, Amati B. Mol Oncol 16: 2022 1132-1152	3
Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Bal E, Kumar R, Hadigol M, Holmes AB, Hilton LK, Loh JW, Dreval K, Wong JCH, Vlasevska S, Corinaldesi C, Soni RK, Basso K, Morin RD, Khiabanian H, Pasqualucci L, Dalla-Favera R. Nature 607: 2022 808-815	15